News & Updates
Parker Institute Touts Early Results in Pancreatic Cancer Trial
Tuesday, April 9, 2019
In 2016, Philly Fights Cancer: Round 4 honoree Sean Parker — the founder of Napster and an early investor in Facebook — pledged $250 million to bring together researchers from academic cancer centers across the country with the goal of accelerating the development of new treatments that harness the immune system to attack cancer.
According to a new article from Stat News, the Parker Institute for Cancer Immunotherapy is presenting clinical trial results for the first time. And those results, which come just a year and a half after the first patient was enrolled in the study, show tumor shrinkage from the multi-drug regimen administered to patients with metastatic pancreatic cancer.
The new findings from the Phase 1 clinical trial were unveiled at the American Association of Cancer Research annual meeting underway in Atlanta.
“I don’t want to look too far down the road, but these results are impressive,” Dr. Robert Vonderheide, the Parker Institute investigator in charge of the trial and director of the Abramson Cancer Center of the University of Pennsylvania, said in an interview with STAT.
In 2016, Penn Medicine’s Abramson Cancer Center joined the Parker Institute for Immunotherapy, a collaborative research partnership that allows a group of international teams to further work towards the goal of fighting and curing cancer together. Philly Fights Cancer benefits the life-saving clinical trials and translational research taking place at the Abramson Cancer Center.
To read more about the findings of the clinical trials and what this means for the future of pancreatic cancer, see the full article below.
Share this post
In 2016, Philly Fights Cancer: Round 4 honoree Sean Parker — the founder of Napster and an early investor in Facebook — pledged $250 million to bring together researchers from academic cancer centers across the country with the goal of accelerating the development of new treatments that harness the immune system to attack cancer.
According to a new article from Stat News, the Parker Institute for Cancer Immunotherapy is presenting clinical trial results for the first time. And those results, which come just a year and a half after the first patient was enrolled in the study, show tumor shrinkage from the multi-drug regimen administered to patients with metastatic pancreatic cancer.
The new findings from the Phase 1 clinical trial were unveiled at the American Association of Cancer Research annual meeting underway in Atlanta.
“I don’t want to look too far down the road, but these results are impressive,” Dr. Robert Vonderheide, the Parker Institute investigator in charge of the trial and director of the Abramson Cancer Center of the University of Pennsylvania, said in an interview with STAT.
In 2016, Penn Medicine’s Abramson Cancer Center joined the Parker Institute for Immunotherapy, a collaborative research partnership that allows a group of international teams to further work towards the goal of fighting and curing cancer together. Philly Fights Cancer benefits the life-saving clinical trials and translational research taking place at the Abramson Cancer Center.
To read more about the findings of the clinical trials and what this means for the future of pancreatic cancer, see the full article below.